CT-guidance interstitial 125Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors by Qianqian Cao et al.
Cao et al. Radiation Oncology  (2014) 9:301 
DOI 10.1186/s13014-014-0301-8RESEARCH Open AccessCT-guidance interstitial 125Iodine seed
brachytherapy as a salvage therapy for
recurrent spinal primary tumors
Qianqian Cao1, Hao Wang1, Na Meng1, Yuliang Jiang1, Ping Jiang1, Yang Gao1, Suqing Tian1, Chen Liu2,
Ruijie Yang1, Junjie Wang1* and Kaixian Zhang3*Abstract
Background: Management of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT).
Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to
evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral
primary tumors.
Methods: From November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively
reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%)
had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific
activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of
125I seeds were 90–183 Gy
(median 137 Gy). The follow-up period ranged from 2 to 69 months (median 19 months). The local control rate was
calculated by the Kaplan-Meier method.
Results: For 5 Chondrosarcomas, the 1-, 2-, 3-year local control rates were 75%, 37.5%, and 37.5%, respectively, with
a median of 34 months (range, 4–39 months). For 4 chordomas, the local control rate was 50% with a median
follow-up of 13 months (range, 3–17 months). For 3 fibromatosis, all of them were survival without local recurrence
at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed
local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and
normal or improved ambulation, without more than Frankel grade 3 radiation myelopathy.
Conclusions: Percutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal
primary tumors.
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Primary spinal tumors which can be benign or malignant
are relatively uncommon compared with metastases to
the spine [1]. Common benign tumors in the spine in-
clude osteoid osteoma, osteoblastoma, aneurysmal bone
cysts, osteochondroma and giant cell tumor. Malignant
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unless otherwise stated.myeloma, osteosarcoma, chondrosarcoma, plasmacytoma
and Ewing’s sarcoma. These various types of tumor result
in a broad spectrum of symptoms ranging from backache
to paraplegia. Initial presenting symptoms may include
neural dysfunction, local pain or spinal deformation.
Given the complex structure of the spine, the biological
characteristics vary among different malignancies, leading
to differing sensitivities to chemotherapy and EBRT [2].
To deliver appropriate treatment, it is important that radi-
ation therapists understand each type of neoplasm.
Primary paraspinous and vertebral column tumors are
relatively uncommon and their treatment is a challen-
ging problem due to the anatomic location and organsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients characteristics (n = 17)
No. of patients Percentage (%)

















Malignant giant cell tumor 1 5.9
Malignant vertebral hemangioma 1 5.9
Previous surgery 14 82.4
Previous EBRT 15 88.2
Previous chemotherapy 3 17.6
Follow-up (months)
Median (months) (range) 19 (2-69)
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primary spinal tumors has been open surgical excision,
though corporectomy and spondylectomy are not wide
anatomical resection indeed [3,4]. EBRT also plays a prom-
inent role because of the significant side effects and disad-
vantages of surgery [5,6]. However, due to coexisting
medical problems or unacceptable surgical complication
risks, many patients are not candidates for surgery or EBRT
[7]. A treatment modality with improved outcomes, good
tolerability and a short hospital stay is therefore needed.
CT-guided 125I seed implantation therapy has been the
focus of recent studies that have demonstrated excellent
clinical outcomes [8], but has rarely been reported in the
treatment of recurrent spinal primary tumors [9]. Here
we report our initial results with 125I seed brachytherapy
for recurrent paraspinous and vertebral column tumors
and discuss the possible advantages of this technology.
Materials and methods
Characteristics of patients
In this study, we retrospectively reviewed 17 patients
who were treated at our department between November
2002 and June 2014. There were 13 men and 4 women
with a median age of 52 years (range 20–71 years). 5
had chondrosarcoma, 4 were chordoma, 3 fibromatosis
and the last 5 were paraganglioma, lymphoma, osteo-
sarcoma, malignant giant cell tumor and vertebral
hemangioma, respectively (Table 1). The tumors involved
the arch as well as the vertebral body in 35.3% patients,
while 64.7% involved the vertebral body alone. Before
undergoing interstitial 125I brachytherapy, all 17 patients
had previously undergone treatment to the spine, 14 had
undergone corporectomy or spondylectomy and tumor re-
section, 15 had received EBRT (the total cumulative doses
of 39.6-78 Gy, with a median of 54 Gy) and 3 had received
chemotherapy (Table 2). All patients were normal for heart,
liver, kidney and blood functional markers and showed no
signs of infection. Life expectancy was more than 6 months.
Before administration of the radioisotope, informed
signed consent was obtained in accordance with our qual-
ity assurance program. The study followed the guidelines
for experimental investigation with human subjects re-
quired by our institution. This retrospective research has
been approved by the ethics committee in Peking University
3rd Hospital and carried out in accordance with the
Helsinki Declaration [10]. The inclusion criteria for the
study were: Karnofsky performance status (KPS) >60; def-
inite pathological diagnosis; isolated or limited number of
malignant tumors;recurrent or residual spinal tumors after
irradiation and/or chemotherapy; residual tumors after sur-
gery resection; for both malignant and benign paraspinal
lesions, patients underwent seed implantation because
they refused or their status did not allow surgery or
chemoradiotherapy; tumor identified on CT beforeimplantation; and follow-up until death. Exclusion cri-
teria were as follows: poor general health or serious med-
ical condition present that meant the patient could not
tolerate implantation; poor coagulation function; radi-
ation resistance; and no proper path for the needles.
Preparation of seed implants
Many specialized devices have been developed to in-
crease the precision and accuracy of dose delivery. To
determine accurately the seeds’ position, CT guidance
was used (64 slice spiral; Lightspeed VCT; GE Healthcare,
Piscataway, NJ). Radioactive 125I seeds were provided by
the China Institute of Atomic Energy (model 6711; Beijing
Atom and High Technique Industries Inc., Beijing, China),
of size 0.8 mm× 4.5 mm and activity 0.50-0.80 mCi. For
implantation, 18G needles and a Mick applicator (Mick
Radio-Nuclear Instruments Inc., Mount Vernon, NY)
were used. The radiation oncologist contoured the gross
tumor volume (GTV) on each transverse image, the plan-
ning target volume (PTV) included 0.5-1.0 cm of GTV
peripheral tissue. A three-dimensional (3D) EBRT planning
system (Beijing Fei Tian Industries Inc., Beijing, China)
Table 2 General information of patients before 125I seed implantation (n = 17)
No. Gender Age Pathological diagnosis Location Pre-seed implant therapy PS:NRS ASIA Ambulatory function score
1 Male 59 Chordoma S3 S+RT60Gy 5-6 E
2 Male 69 Chondrosarcoma T9-11 S 4 B
3 Male 50 Chondrosarcoma L2-S1 S+RT60Gy 8-9 C
4 Male 50 Parganglioma L1-L2 S+RT46Gy 4-6 C
5 Male 71 Chondrosarcoma C2-5 S 3 D
6 Male 45 Chondrosarcoma L3,4 S+RT64Gy+CTx 4-5 D
7 Female 20 Lymphoma S1-5 CTx+RT54Gy 6 C
8 Male 46 Osteosarcoma S1-5 CTx+RT54Gy 4 E
9 Female 57 Fibromatosis C3-T2 RT60Gy 3 E
10 Male 47 Chondrosarcoma C4-T3 S+RT64Gy 3-4 D
11 Male 69 Chordoma S3 S+RT50Gy 4 E
12 Male 52 Chordoma C2-4 S+RT44Gy 1 D
13 Female 57 Chordoma C2 S+RT40Gy 2 D
14 Female 46 Fibromatosis T1-3 S+RT78Gy 2 D
15 Female 68 Malignant giant cell tumor T1 S+RT39.6Gy 6 C
16 Male 56 Fibromatosis C5 S+RT50Gy 4 C
17 Male 52 Malignant vertebral hemangioma C2 S+RT40Gy+CTx 5-7 C
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late the number and dose rate distribution of 125I seeds.
The D90 (the doses delivered to 90% of the target volume
defined by CT using dose-volume histogram) was 90–
183 Gy (median 137 Gy, over the period of total decay)
and the number of seeds per patient ranged from 7–122
(median 79). The treatment efficacy, with regard to dose
validation, was evaluated from a dose-volume histogram
after the procedure.
Treatment protocols
During the procedure, patients remained in a prone pos-
ition to facilitate CT guidance. We measured the pedicle
angle and the distance of the puncture point from the
spinous process, which was maintained at 1.0 cm. The
depth of the puncture point to the pedicle was also
borne in mind. After administration of local anesthesia,
for cervical, thoracic and lumbar neoplasms, needles
were inserted through the anterior portion of the lateral
images, in the interval between the pedicle and the verte-
bral body, or with a pedicle or paraspinal approach, re-
spectively. Radioactive seeds were implanted in accordance
with the principles of Paris [11], in a linear arrangement,
parallel and 0.5-1.0 cm apart. Seeds were implanted 1.0 cm
from the spinal cord, to minimize radiation damage. Im-
mediately after the procedure, a CT scan was obtained to
confirm the location of the seeds in case of any need for
supplementary implantation. Patients remained in bed for
6 h with routine hemostatic treatment and antibiotic
prophylaxis, and their vital signs were observed.Follow-up and statistical analyses
Tumor response was initially evaluated clinically and
radiologically at 4 weeks and thereafter at intervals of
2 months for the first year and every 6 months thereafter.
Local control time was measured from the beginning of
therapy. We used a numeric rating scale (NRS) to measure
pain scores as follows: 0, no pain; 1–3, mild pain; 4–6,
moderate pain causing insomnia; 7–10, severe pain.
Frankel was used for measuring radiation myelopathy.
American Spinal Injury Association (ASIA) grade was ap-
plied for neurological assessment. The Radiation Therapy
Oncology Group/European Organisation for Research and
Treatment of Cancer radiation injury grading was used to
evaluate side effects after implantation. Local control rates
were generated by the Kaplan-Meier method and SPSS
18.0 (IBM, Armonk, NY) was used for statistical analysis.
Results
Treatment efficacy
17 patients (100%) were followed-up, with a median
follow-up time of 19 months (range 2–69 months).
Symptom and local control were achieved in all 17 pa-
tients (100%). None was lost to follow-up. All cases were
assessed clinically and with imaging until the follow-up
time or death.
From CT images obtained post-seed implant, all 125I
seed distributions in GTV and 0.5-1.0 cm tumor margin
were seen to meet the design requirements. The average
number of seeds per patient was 79 (range 7–122), the
median specific activity was 0.7 mCi (range 0.5-0.8 mCi)
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V100 and V90 for GTV were showed in Table 3, with pre-
scribed dose 110 Gy. For all the patients, the V90 > 90%
which was in accordance with our pre-plan. The median
maximum dose for spinal cord was 36.3 Gy (range 22–
123.2 Gy), for cauda equina, the median maximum dose
was 79.5 Gy (range 27–121 Gy). The median maximum
dose of esophagus was 28.9 Gy (range 14–42 Gy). The
median maximum dose of bowel was 65 Gy (range 62.5-
78.2 Gy). Other OARs all meet with the tolerance con-
straints. At follow-up, all patients were found to have
tolerated the procedure, with no need for removal of
seeds or cases of pulmonary embolism, and none experi-
enced radiation-induced complications or disease (Table 3,
Figure 1, Figure 2).
Local control and survival
3 (17.6%) patients demonstrated tumor recurrence at 8,
14 and 34 months, which received a second round of
seed implants. 1 patient died 3 months after the second
seed implantation and experienced metastases. The other 2
manifested local survival at the end of follow-up. 6 of the
17 patients (35.3%) died during follow-up and 11 (64.7%)
remained alive at the end of follow-up. For 5 chondrosar-
comas, the 1-, 2-, 3- year local control rate were 75%,
37.5%, and 37.5%, respectively, with a median of 34 months
(range, 4–39 months). For 4 chordomas, the local control
rate was 50% with a median follow-up of 13 months
(range, 3–17 months). For 3 fibromatosis, all of them were
survival without local recurrence at the end of follow-up.
And for others with 1 case, the outcomes could be seen in
Table 3. All deaths were due to multiple organ failure.
Pain relief
All patients suffered varying degrees of pain before seed
implantation, ranging from 1 to 9 on the NRS. The
mean time to pain relief was 2–3 days after the proced-
ure. 1 to 3 months postimplant, all patients experienced
easing of pain. Mean NRS scores before and after im-
plantation were 4.48 ± 2.03 and 1.18 ± 1.38, respectively.
The efficacy rate was 100% (P < 0.05).
Neurological and ambulatory function
Regarding neurologic function, 11 patients improved ac-
cording to ASIA grade. 1 grade B became C, 4 grade Cs
became Ds, 1 grade C became E and 5 grade Ds became
Es. Regarding ambulatory function, 9 patients improved
and 2 patients who had been confined to bed before the
procedure due to pain recovered sufficiently to under-
take daily activities.
Complications
Only 1 of 17 patients suffered localized bone defects and
bone fractures. In this case, before implantation, bonedefects can be seen in CT, and after implantation, the le-
sion size was the same as before, not worsen by radioactive
seeds. The mean dose to the involved vertebral body was
121 Gy. 1 developed pitting edema of both lower legs
30 months later. 1 patient complained of pigmentation and
desquamation on local skin, corresponding to a grade 1
skin reaction. Such symptoms were relieved by application
of trolamine cream (Biafine) for several days.
Discussion
The gold standard and first line treatment for spinal tu-
mors is surgery, but due to the short expected lifespan
of these patients surgical resection has limited clinical
benefit. EBRT kills tumor tissue and has advantages of
providing pain relief, preventing skeletal related events
such as pathologic bone fracture [12], and reducing the
size of tumors before surgical resection. Spinal radiosur-
gery was pioneered by Hamilton et al. in 1995 [13], with
the successful treatment of a cohort of five patients. The
effects of radiotherapy lag a little behind those of sur-
gery. Generally, it is 10–20 days before pain is reduced
or disappears. In addition, EBRT is performed without
spinal stabilization. Bone reconstruction should begin 2–
4 months after EBRT [14], and this delay of bone remodel-
ing can increase the incidence of vertebral collapse, which
in turn leads to pain and symptoms of nerve compression.
Furthermore, radiotherapy lacks precision and sometimes
less than optimal doses are given to reduce irradiation of
the spinal cord [15]. Rogers reported on EBRT combined
with brachytherapy that delivered 69.9 Gy to the spinal
cord [9], the mean follow-up time was 19.8 months
and no patient exhibited radiation myelitis, even with
167.3 Gy. Armstrong treated paraspinal tumors, Pancoast
carcinoma and other sarcomas with permanent or tem-
porary brachytherapy, the dose to the spinal cord was
60 Gy, without occurrence of myelitis [16]. Other reported
complications include paresthesia, fatigue, dysphagia, noc-
turia, diarrhea and radiculitis, though these resolve or are
rare with modern dose planning and fractionation systems
[17]. The dose tolerance for organs at risk could be better
contoured.
Vitaz et al. reported that prior adjuvant treatment mo-
dalities such as chemotherapy or EBRT typically increase
perioperative morbidity and mortality following spinal
surgery [18]. The best surgical outcomes are achieved
with radical resection of the tumor (removal of the
whole spine) [19]. Palliative surgery is less effective, espe-
cially in patients with a short survival expectancy accord-
ing to the Tokuhashi and Tomita spinal tumor grading
systems [20-22]. To achieve complete tumor resection,
good visualization is of great importance. Open access
procedures such as thoracotomy may be used with min-
imal injury to the surrounding structures and prevention
of future spinal instability, but these open approaches can
Table 3 Characteristics of 125I seed implantation and outcome (n = 17)








RR LR (m) Follow-up (m) Cause of
death
1 1.5×1.5×1.0 9.9 0.5/90 92.4/95.2 7 Palliative Surgery 2-3 E PR 13 69 MM
2 8.5×7.5×7.0 110.2 0.5/100 93.2/96 80 Seed implant 0-1 C PR 8 11 MM
3 5.5×4.5×11 104.1 0.8/100 90.1/94.2 79 No 5-6 C SD 39 41 MM
4 2.7×1.5×5.0 102.8 0.8/140 93.2/96.7 92 No 1-2 D PR 32 32 MM
5 2.5×2.0×1.6 32.6 0.7/121 92.8/94.5 45 Seed implant 0-1 E CR 34 36 MM
6 5.5×4.1×1.7 103.8 0.72/108 89.2/93.2 109 No 1-2 D PR 19 19 MM
7 6.2×10.7×8.3 100.3 0.75/148 96.8/99.2 100 CTx 0-1 D CR 36 36 S
8 8.1×6.3×6.8 99.6 0.73/143 97.5/99 103 No 2 E PR 35 35 S
9 11.5×3.1×3.5 39.6 0.7/102 87.8/90.7 44 No 0-1 E PR 21 21 S
10 6.0×3.2×4.1 73.1 0.6/150 99/99.7 122 No 1-2 E PR 4 4 MM
11 1.4×4.8×3.9 50.5 0.64/164 95.2/95.9 98 No 2 E PR 17 17 S
12 4.6×3.5×7.7 46.2 0.68/152 98.6/99.3 74 No 0 E PR 3 3 S
13 4.5×6.4×4.3 27.4 0.7/152 95.1/96.4 47 No 0 E SD 3 3 S
14 6.0×5.0×4.0 27.8 0.65/133 98.1/99.3 48 No 1 E PR 12 12 S
15 6.0×3.5×4.5 60.5 0.74/122 93.5/96.2 85 No 3 D PR 11 11 S
16 2.3×1.8×1.2 22.9 0.75/137 96.3/98.2 31 No 2 D SD 2 2 S












Figure 1 The isodose curve distribution of tumor after seed
implantation from CT scan. The inner green curve represents GTV.
The ellipses are isodose lines of 160, 120, 80 Gy from inside, respectively.
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long hospital stays. Kan et al. used video-assisted thoraco-
scopic surgery to treat primary tumors of the spinal axis,
patients with paraspinal neurogenic tumors had an excel-
lent clinical outcome, especially those without intradural
extension [23]. Percutaneous vertebroplasty (PVP) is an-
other minimally invasive treatment for spinal malignancies
[24,25]. Compared with traditional procedures, PVP is su-
perior for spinal stabilization. Candidates include patients
with vertebral hemangioma, vertebral myeloma and verte-
bral metastases [26,27]. In patients in poor general health,
PVP has become an effective option. Pain relief in 24 h
has been reported and the result was more than 90%
[28-30]. For patients with relatively large scale vertebralFigure 2 The Dose volume histograms of GTV and spinal cord after sdestruction or a high incidence of fractures, PVP or PVP
with radioactive seed brachytherapy is the preferred
treatment [31].
In order to protect normal tissues for repeat irradi-
ation spinal tumors, Memorial Sloan-Kettering Cancer
Center was the first in the world who used HDR tech-
nique for spinal tumors [32]. Most HDR therapies were
operated intraoperatively, for both 32P plaques and cathe-
ters with 192Ir after-loading system. Folkert et al. reported
32P for 3 recurrent spinal sarcomas, the local control rate
was 62.5% with a mean follow-up of 10.2 months, which is
not better than ours (1 case, 35 months after implantation,
still survived) [32]. For 192Ir HDR in repeat irradiated le-
sions of spine, another study by Folkert et al. showed 5 pa-
tients received single-fraction with a median dose of
14 Gy, 2 patients placed catheters intraoperatively and 3
with image-guided techniques [33]. The median follow-up
was 9 months, and at the end of follow-up, no local pro-
gression was observed, the pain relief can be gained in 4
patients (80%) 1–4 weeks later. In our study, all patients
experienced pain relief at the end of follow-up, the mean
time to pain relief was 2–3 days after the procedure. The
median D90 in our cases was 137 Gy. The
125I seeds im-
plantation was minimally invasive, local anesthesia was
enough in general, but for HDR general anesthesia was
used [33].
125I seeds has developed considerably in the past
20 years and plays an important role in the salvage treat-
ment of many malignancies, for both local control and
control of metastatic disease [34,35]. With its features of
low energy, homogenous dose distribution in the local
area, sharp dose gradient between tumor and adjacent
normal tissues and protection of organs at risk, intersti-
tial 125I seed brachytherapy seems to be an effective
salvage approach. CT allows the visualization of smalleed implantation.
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involvement and the extent of spinal cord invasion
[36,37]. The sensitivity and diagnostic accuracy are 66%
and 89%, respectively [38]. For spinal tumors, patient se-
lection remains the most important factor in the success
of the procedure. CT-guided 125I seed brachytherapy is
suitable for those who are poor candidates for surgical
intervention as assessed by the Enneking or WBB grad-
ing system [39], who have recurrent tumor after surgery
and EBRT, or who are reluctant to undergo an open sur-
gical procedure or EBRT. Rogers et al. delivered 69.9 Gy
to the spinal cord without radiation myelitis, but the rec-
ommended clinical dose limit is 45 Gy [9]. Wang et al.
reported 19 patients who underwent interstitial 125I seed
brachytherapy, the median minimal peripheral dose
(MPD) was 120 Gy, median follow-up was 22 months.
1-, 2-, 3- and 5-year local control rates were 63%, 47%,
31% and 3%, respectively. 1-, 2-, 3- and 5-year survival
rates were 74%, 56%, 43% and 43%, respectively [40]. No
myelopathy were encountered. In the present study, nei-
ther neurological complications nor radiological abnor-
malities were recorded at the end of follow-up. The
mean KPS was more than 60 before the procedure and
all patients had better scores afterwards. Rose et al.
found kyphosis to be the most commonly observed clin-
ical deformity secondary to compression fractures and
decreased ambulation [41]. In our series, only one pa-
tient suffered bone fracture during follow-up. All of
them experienced pain relief and 81.8% had an improved
ambulation score, which is in accordance with the find-
ings of Rogers, who treated 24 patients with 125I seed
brachytherapy with a 2 year local control rate and 1 year
OS of 87.4% and 40%, respectively, improved ambulation
score in 84% of patients and resumed activities in 67%
[9]. In our study, 11.8% patients who were confined to
bed before the procedure were able to resume activities.
Conclusion
In the present study, interstitial 125I seed brachytherapy
appears to achieve a high rate of tumor control and
rapid pain relief. This study demonstrated that CT-
guided 125I seed for recurrent spinal primary tumors is
both safe and effective. However, in the case of large
volume or irregular shape, the edge of tumors may be
overlooked. In addition, the actual seeds number and
positions can’t match perfectly with preoperative plan
due to personal equation, which leads to great import-
ance of dose verification [42]. Therefore, strict adherence
to the scientific method remains crucial. Our study ap-
pears lack of controlled group and long term follow-up
results, in order to determine the indications, risks and
benefits of 125I seed brachytherapy compared with more
conventional approaches, large numbers of patients and
prospective studies are needed.Abbreviations
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